Efficacy and tolerability of abatacept treatment: results of 12 months observation
- 作者: Borisova M1, Lukina G1,2, Sigidin Y1, Aronova E1, Luchihina E3, Karateev D3, Glukhova S1, Nasonov E1,4
-
隶属关系:
- V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatment
- Moscow Clinical Scientific Center named after Loginov A.S
- Moscow Regional Research and Clinical Institute (MONIKI)
- I.M. Sechenov First Moscow State Medical University
- 期: 卷 90, 编号 5 (2018)
- 页面: 44-49
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32744
- DOI: https://doi.org/10.26442/terarkh201890544-49
- ID: 32744
如何引用文章
全文:
详细
作者简介
M Borisova
V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatment
Email: mrs.mbrs@yandex.ru
м.н.с., лаб. мониторинга безопасности антиревматических препаратов; https://orcid.org/0000-0002-3674-8518 Moscow, Russia
G Lukina
V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatment; Moscow Clinical Scientific Center named after Loginov A.Sв.н.с., лаб. мониторинга безопасности антиревматических препаратов; руководитель московского городского ревматологического центра Moscow, Russia
Y Sigidin
V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatmentв.н.с., лаб. мониторинга безопасности антиревматических препаратов Moscow, Russia
E Aronova
V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatmentм.н.с., лаб. мониторинга безопасности антиревматических препаратов Moscow, Russia
E Luchihina
Moscow Regional Research and Clinical Institute (MONIKI)в.н.с. отд-ния кардиопульмонологии Moscow, Russia
D Karateev
Moscow Regional Research and Clinical Institute (MONIKI)главный внештатный специалист-ревматолог, главный н.с. кардиопульмонологического отд-ния Moscow, Russia
S Glukhova
V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatmentн.с. учебно-методического отдела Moscow, Russia
E Nasonov
V.A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatment; I.M. Sechenov First Moscow State Medical Universityнаучный руководитель, акад. РАН, главный внештатный ревматолог, зав. каф. ревматологии ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; каф. ревматологии института профессионального образования Moscow, Russia
参考
- Manders S.H.M, Kievit W, Eddy Adang et al. Cost - effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi - centre randomised trial. Arthritis Research & Therapy. 2015;17(1). http://dx.doi.org/ 10.1155/2013/256871
- Насонов Е.Л., Каратеев Д.Е. Применение блокатора ко - стимуляции Т-лимфоцитов абатацепта при ревматоидном артрите. Науч - практич ревматол. 2010; 4, пр.2:9-27.
- Насонов Е.Л., редактор. Генно - инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013: 16.
- Насонов Е.Л., редактор. Абатацепт. В кн.: Генно - инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013: 221.
- Choy E.H. Selective modulation of T-cell co - stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):510-8.
- Kempis J, Dudler J, Hasler P, et al. Use of abatacept in rheumatoid arthritis. Swiss Med Wkly. 2012 May 11;142:w13581. doi: 10.4414/ smw.2012.13581. PMID: 22581564
- Александрова Е.Н., Новиков А.А., Насонов Е.Л. Роль Т-клеток в патогенезе ревматоидного артрита. Науч - практич ревматол. 2010; 4, пр.2:3-9.
- Nam J.L, Winthrop K.L, van Vollenhoven R.F et al. Current evidence for the management of rheumatoid arthritis with biological disease - modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573
- Gaujoux-Viala C, Smolen J.S, Landewé R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease - modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010 Jun;69(6):1004-9. doi: 10.1136/ard.2009
- Kremer J.M, Genant H.K, Moreland L.W et al. Results of a two - year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008 Apr; 58(4):953-963. doi: 10.1002/art.23397
- Schiff M, Keiserman M, Codding C et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open - label extension of the ATTEST Study. Ann Rheum Dis. 2011 Nov; 70(11):2003-7. doi: 10.1136/ annrheumdis-2011-200316.
- Genovese M.C, Becker J.C, Schiff M et al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Engl J Med 2005; 353:1114-1123 Sept 15, 2005. doi: 10.1056/NEJMoa050524.
- Weinblatt M, Combe B, Covucci A et al. Safety of the Selective Costimulation Modulator Abatacept in Rheumatoid Arthritis Patients Receiving Background Biologic and Nonbiologic Disease-Modifying Antirheumatic Drugs. A One-Year Randomized, Placebo-Controlled Study. Arthritis Rheum. 2006 Sep; 54(9): 2807-2816. doi: 10.1002/ art.22070
- Schiff M, Pritchard C, Huffstutter J.E et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti - tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009 Nov;68(11):1708-14. doi: 10.1136/ard.2008.099218
- Wells A.F, Westhovens R, Reed D.M et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate - naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011 Nov;38(11):2362-8. doi: 10.3899/jrheum.110054
- Emery P, Durez P, Dougados M et al. Impact of T-cell costimulation modulation in patients with undifferentiated infl ammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010 Mar;69(3):510-6. doi: 10.1136/ard.2009.119016
- Dudler J, Tuerk R, Handschin T et al. RAISE - rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation. Swiss Med Wkly. 2013 Dec 6;143:w13849. doi: 10.4414/smw.2013.13849
- Nüßlein H.G, Alten R, Galeazzi M et al. Real - world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14
- Leffers H.C, Østergaard M, Glintborg B et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases. 2011;70:1216-1222.
- Truchetet M-E, Poursac N, Barnetche T et al. Abatacept monotherapy compared with abatacept plus disease - modifying anti - rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. Arthritis Research & Therapy. 2016;18:72. doi: 10.1186/s13075-016-0956-7
- Weinblatt M.E, Moreland L.W, Westhovens R et al. The Journal of Rheumatology, June 2013; 40 (6): 787-797. doi: https://doi.org/ 10.3899/jrheum.120906
- Takahashi N, Kojima T, Kaneko A et al. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity Clin Rheumatol. 2014; 33: 39. https://doi.org/10.1007/s10067-013-2392-2
- Hirabara S, Takahashi N, Fukaya N et al. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol. 2014;33:1247. https://doi.org/10.1007/s10067-014-2711-2
- Лукина Г.В., Сигидин Я.А., Мазуров В.И. и др. Предварительные результаты применения абатацепта в клинической практике. В кн.: Генно - инженерные биологические препараты в лечении ревматоидного артрита. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2013: 386-387.
- Мазуров В.И., Долгих С.В., Жугрова Е.С., Шульман Ю.Б., Самигуллина Р.Р. Опыт применения абатацепта в лечении больных ревматоидным артритом. Науч - практич ревматол. 2011;49(6):14-16. doi: 10.14412/1995-4484-2011-513
- Борисова М.А., Лукина Г.В., Сигидин Я.А., Лучихина Е.Л., Каратеев Д.Е., Аронова Е.С., Глухова С.И. Сравнительная оценка эффективности и безопасности абатацепта у пациентов с разной длительностью ревматоидного артрита. Науч - практич ревматол. 2016;54(6):667-673. doi: 10.14412/1995-4484-2016-667-673
- Arnett F.C, Edworth S.M, Bloch D.A et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31:315-24. doi: 10.1002/art.1780310302
- Aletaha D, Neogi T, Silman A.J. et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthr Rheum. 2010;62:2569-2581. doi: 10.1002/ art.27584
- Каратеев Д.Е., Лучихина Е.Л., Муравьев Ю.В., Демидова Н.В., Гринева Г.И., Новикова Д.С., Александрова Е.Н., Новиков А.А., Смирнов А.В., Волков А.В., Авдеева А.С., Лопарева Е.В., Олюнин Ю.А., Лукина Г.В., Попкова Т.В., Насонов Е.Л. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Науч - практич ревматол. 2013;51(2):117-125. doi: 10.14412/1995-4484-2013-637
- Каратеев Д.Е., Лучихина Е.Л., Демидова Н.В., Гриднева Г.С., Канонирова М.А., Муравьев Ю.В., Лукина Г.В., Олюнин Ю.А., Касумова К.А., Александрова Е.Н., Новиков А.А., Авдеева А.С., Попкова Т.В., Новикова Д.С., Смирнов А.В., Волков А.В., Насонов Е.Л. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА): результаты лечения 130 больных в течение 12 месяцев. Науч - практич ревматол. 2015;53(5s):77-84. doi: 10.14412/1995-4484-2015-77-84
- Fransen J, Stucki G, van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum. 2003;49:214-24. doi: 10.1002/art.11407
- Aletaha D, Nell V, Stamm T et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther. 2005;7(4):796-806. doi: 10.1186/ar1740
- Pincus T, Swearingen C, Wolfe F. Toward a multy - dimensional Health Assessment Questionnaire (MDHAQ) - assessment of advanced activities of daily living and psychological status in the patient - friendly health assessment questionnaire format. Arthr Rheum.1999;42:2220-30. doi: 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0. CO;2-5
- Kosinski M, Zhao S.Z, Dedhiya S et al. Determing minimally important changes in generic and disease - specific health - related quality of life questionaries in clinical trials of rheumatoid arthritis. Arthr Rheum. 2000;43(7):1478-87. doi: 1002/1529-0131(200007) 43:7%3C1478::AID-ANR10%3E3.0CO;2-M.
- Rintelen B, Sautner J, Haindl P.M et al. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol. 2009;38(5):336-41. doi: 10.1080/03009740902932835.
- Medeiros, Marta Maria das Chagas, Oliveira, Brenda Maria Gurgel Barreto de, Cerqueira, João Victor Medeiros de, Quixadá, Raquel Telles de Souza, & Oliveira, Ídila Mont’Alverne Xavier de. (2015). Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut -off points in a Northeastern Brazilian population. Revista Brasileira de Reumatologia. 2014;55(6): 477-484. https://dx.doi.org/10.1016/j.rbr.2014.12.005
- Leeb B.F, Andel I, Sautner J et al. Disease activity measurement of rheumatoid arthritis: Comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum. 2005 Feb 15;53(1):56-60.